Russia’s potential coronavirus vaccine shows ‘no serious adverse’ effects and creates antibody response: The Lancet study

A medical worker holds a syringe with a flu vaccine in a mobile flu vaccination center in central Moscow. centers.

Vyacheslav Prokofyev | TASS | Getty Images

Early results from trials of Russia’s potential coronavirus vaccine show no major negative side effects, a study published in peer-reviewed medical journal The Lancet revealed Friday.



“Preliminary results from Russian trials find that #COVID19 vaccine candidates led to no serious adverse events and elicit antibody response,” a tweet from the journal’s Twitter account read. 

Doctors involved in the trials conducted “two open, non-randomised phase 1/2 studies at two hospitals in Russia,” on 76 healthy volunteers aged 18 to 60, the Lancet article said. It added that the vaccine formulations tested were “safe and well tolerated.” 

“The two 42-day trials – including 38 healthy adults each – did not find any serious adverse effects among participants, and confirmed that the vaccine candidates elicit an antibody response,” the study’s authors wrote.

It added: “Large, long-term trials including a placebo comparison, and further monitoring are needed to establish the long-term safety and effectiveness of the vaccine for preventing COVID-19 infection.”

‘Sputnik V’

The vaccine, dubbed “Sputnik V” in Russia, became the first in the world to be registered after it was approved by the country’s health regulators last month. Russian President Vladimir Putin said at the time that full-scale production was due to start in September.

The news led to criticism from around the world amid questions as to its safety and efficacy. At the time, the vaccine had undergone rapid Phase 1 and 2 clinical trials on a small number of people but no data from them had been published. The Lancet study marks the first time trial results have been published in an well-respected international publication.

Kirill Dmitriev, the chief of Russian sovereign wealth fund RDIF which is backing the vaccine, hailed The Lancet’s report as validation of his country’s efforts in an interview with CNBC.

“We had lots of interest in the Russian vaccine (with) publication in the Lancet, which is one of key Western magazines on medicine,” Dmitriev told CNBC’s Julianna Tatelbaum. “It is very important to share information with the world … the results have been very good but basically the study showed there is very strong both antibodies and cell immune response.”

He added that Russia was “on track” to provide exports of the vaccine by November.

The Lancet is one of the world’s oldest medical journals, with editorial offices in New York, London and Beijing. 


Originally published on CNBC

S&P 500 
$3,288.47  $27.10 
NASDAQ 100 
$11,015.00  $171.38 
Dow Jones Industrial Average 
$27,169.27  $118.91 
Apple Inc. 
$109.97  $1.84 
Alphabet Inc. 
$1,432.84  $32.62 
MICROSOFT CORP 
175,60 €  2,90 € 
Tesla, Inc. 
$387.64  $36.59 
Berkshire Hathaway Inc. 
$319,067.00  $1.00 
AbbVie Inc. 
$88.64  $0.0400 
Costco Wholesale Corporation 
$344.85  $0.4000 
Smartsheet Inc. 
$48.06  $0.2300 
Zai Lab Limited 
$75.64  $0.3900 
Western Digital Corporation 
$39.66  $3.19 
NVIDIA Corporation 
$500.25  $5.26 
Gold Dec 20 
$1,868.80  $38.80 
Crude Oil Nov 20 
$39.81  $0.0100 
BTC/USD 
$10,468.27  $70.20 
Bitcoin Cash USD 
$215.05  $4.96 
LTC/USD 
$44.50  $0.0400 
ETH/USD 
$338.81  $5.70 
Dogecoin USD 
$0.0026  $0.0000